Satish Jindal appointed to lead drug discovery at Allied-Bristol Life Sciences

6 October 2014

Satish Jindal has been appointed to lead the discovery of drug candidates from leading academic institutions at Allied-Bristol Life Sciences, a jointly-owned enterprise between Allied Minds (LSE: ALM) and US drug major Bristol-Myers Squibb (NYSE: BMY).

He recently headed Bristol-Myers Squibb’s research and development center in Bangalore, India, focusing on discovery and early development of drug candidates in several disease areas. Under Dr Jindal’s leadership, Allied-Bristol will have access to the scientific expertise from Bristol-Myers and Biocon Bristol-Myers Squibb Research and Development Center.

Dr Jindal joined Bristol-Myers Squibb in 2011 as part of the team that collaborated with Allied Minds to create Allied-Bristol Life Sciences earlier this year. Previously, he had formed and built biotech companies including Vedantra, an immunotherapy company he co-founded based on intellectual property from the Koch Institute at the Massachusetts Institute of Technology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK